SERCA2a is an important therapeutic target in heart failure, with ongoing clinical gene therapy trials expected to provide answers on its safety and applicability.
Does SERCA2a targeted gene therapy improve outcomes in heart failure?
SERCA2a is a promising therapeutic target for heart failure, with gene therapy showing efficacy in animal models and currently being evaluated in clinical trials.
The cardiac isoform of the sarco/endoplasmic reticulum Ca(2+)ATPase (SERCA2a) plays a major role in controlling excitation/contraction coupling. In both experimental and clinical heart failure, SERCA2a expression is significantly reduced which leads to abnormal Ca(2+) handling and deficient contractility. A large number of studies in isolated cardiac myocytes and in small and large animal models of heart failure showed that restoring SERCA2a expression by gene transfer corrects the contractile abnormalities and improves energetics and electrical remodeling. Following a long line of investigation, a clinical trial is underway to restore SERCA2a expression in patients with heart failure using adeno-associated virus type 1. This review addresses the following issues regarding heart failure gene therapy: i) new insights on calcium regulation by SERCA2a; ii) SERCA2a as a gene therapy target in animal models of heart failure; iii) advances in the development of viral vectors and gene delivery; and iv) clinical trials on heart failure using SERCA2a. This review focuses on the new advances in SERCA2a- targeted gene therapy made in the last three years. In conclusion, SERCA2a is an important therapeutic target in various cardiovascular disorders. Ongoing clinical gene therapy trials will provide answers on its safety and applicability.
Lipskaia et al. (2009) conducted a review in Heart failure. SERCA2a-targeted gene therapy was evaluated. SERCA2a is an important therapeutic target in heart failure, with ongoing clinical gene therapy trials expected to provide answers on its safety and applicability.